Bangkok Genomics Innovation Public Company Limited
Stock Exchange of ThailandTotal Valuation
Bangkok Genomics Innovation Public Company Limited carries a market capitalization of 1.32B, placing it among publicly traded companies globally. Its enterprise value stands at 551.65M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.32B |
| Enterprise Value | 551.65M |
Share Statistics
Bangkok Genomics Innovation Public Company Limited currently has 600.00M shares outstanding.
| Shares Outstanding | 600.00M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Bangkok Genomics Innovation Public Company Limited trades at a trailing price-to-earnings ratio of 16.54. The price-to-sales ratio is 1.98, and the price-to-book ratio stands at 2.04.
| PE Ratio | 16.54 |
| PS Ratio | 1.98 |
| PB Ratio | 2.04 |
| P/TBV Ratio | 1.41 |
| P/FCF Ratio | -13.38 |
| P/OCF Ratio | -8.12 |
Enterprise Valuation
On an enterprise value basis, Bangkok Genomics Innovation Public Company Limited trades at an EV/EBITDA multiple of 7.75 and an EV/FCF ratio of 69.74. The EV/Sales ratio of 1.45 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 11.12 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.45 |
| EV / EBITDA | 7.75 |
| EV / EBIT | 11.12 |
| EV / FCF | 69.74 |
Financial Position
Bangkok Genomics Innovation Public Company Limited maintains a current ratio of 4.58, meaning it holds 4.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.88, indicating elevated leverage, while an interest coverage ratio of 49.35 demonstrates strong ability to service its debt obligations.
| Current Ratio | 4.58 |
| Quick Ratio | 3.06 |
| Debt / Equity | 3.88 |
| Debt / EBITDA | 0.30 |
| Interest Coverage | 49.35 |
Financial Efficiency
Bangkok Genomics Innovation Public Company Limited posts a return on equity of 12.53 and a return on invested capital of 8.31.
| Return on Equity (ROE) | 12.53 |
| Return on Assets (ROA) | 6.93 |
| Return on Invested Capital (ROIC) | 8.31 |
| Return on Capital Employed (ROCE) | 12.09 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 7.70 |
Taxes
Over the trailing twelve months, Bangkok Genomics Innovation Public Company Limited has paid 2.52M in income taxes, reflecting an effective tax rate of 5.28.
| Income Tax | 2.52M |
| Effective Tax Rate | 5.28 |
Stock Price Statistics
Bangkok Genomics Innovation Public Company Limited's stock has gained approximately 60.58394% over the past 52 weeks. The 50-day moving average sits at 1.80, while the 200-day moving average is 1.49.
| Beta (5Y) | N/A |
| 52-Week Price Change | 60.58394% |
| 50-Day Moving Average | 1.80 |
| 200-Day Moving Average | 1.49 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Bangkok Genomics Innovation Public Company Limited generated 379.51M in revenue and converted that into 45.35M in net income, yielding earnings per share of 0.08. EBITDA reached 71.16M, while operating income came in at 49.62M.
| Revenue | 379.51M |
| Gross Profit | 155.63M |
| Operating Income | 49.62M |
| Pretax Income | 47.85M |
| Net Income | 45.35M |
| EBITDA | 71.16M |
| EBIT | 49.62M |
| Earnings Per Share (EPS) | 0.08 |
Balance Sheet
Bangkok Genomics Innovation Public Company Limited holds 221.74M in cash and equivalents against 21.47M in total debt, resulting in a net debt position of -221.74M. Total book value stands at 368.49M, with working capital of 453.53M providing operational flexibility.
| Cash & Cash Equivalents | 221.74M |
| Total Debt | 21.47M |
| Net Debt | -221.74M |
| Equity (Book Value) | 368.49M |
| Book Value Per Share | 0.61 |
| Working Capital | 453.53M |
Cash Flow
Bangkok Genomics Innovation Public Company Limited produced -92.32M in operating cash flow over the past twelve months. After subtracting -36.27M in capital expenditures, free cash flow totaled -128.58M - equivalent to -0.21 per share.
| Operating Cash Flow | -92.32M |
| Capital Expenditures | -36.27M |
| Free Cash Flow | -128.58M |
| FCF Per Share | -0.21 |
Margins
Bangkok Genomics Innovation Public Company Limited operates with a gross margin of 41.01, reflecting its pricing power and cost economics. The operating margin of 13.07 and net profit margin of 11.95 provide insight into operational efficiency.
| Gross Margin | 41.01 |
| Operating Margin | 13.07 |
| Pretax Margin | 12.61 |
| Profit Margin | 11.95 |
| EBITDA Margin | 18.75 |
Dividends & Yields
The company's payout ratio of 0.01 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.00 |
| Dividend Yield | N/A |
| Payout Ratio | 0.01 |
| Shareholder Yield | 4.51 |
| FCF Yield | -7.47 |
Scores
Bangkok Genomics Innovation Public Company Limited posts an Altman Z-Score of 4.77, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.77 |